Roivant Sciences (ROIV) EBT (2020 - 2026)

Roivant Sciences (ROIV) has reported EBT for 7 consecutive years, with -$294.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 9.4% year-over-year to -$294.6 million; the trailing twelve-month figure through Jun 2026 stood at -$1.4 billion (down 45.34% YoY), and the FY2026 full-year result was -$264.6 million, up 61.18% from the prior year.
• EBT climbed to -$294.6 million in Q2 2026 per ROIV's latest filing, from -$718.7 million in the prior quarter.
• Across five years, EBT topped out at $5.2 billion in Q4 2023 and bottomed at -$1.0 billion in Q4 2022.
• Historically, EBT has averaged $54.8 million across 5 years, with a median of -$294.6 million in 2026.
• The sharpest annual moves came in 2023 and 2025: EBT surged 592.87% in 2023, then slumped 1270.99% in 2025.
• Over 5 years, EBT stood at -$1.0 billion in 2022, then soared by 592.87% to $5.2 billion in 2023, then sank by 109.29% to -$478.5 million in 2024, then sank by 50.18% to -$718.7 million in 2025, then surged by 59.01% to -$294.6 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$294.6 million, -$718.7 million, and -$159.0 million for Q2 2026, Q4 2025, and Q3 2025 respectively.